A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)
Status:
Completed
Trial end date:
2009-03-12
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and effectiveness of MabThera (rituximab) in patients
with active rheumatoid arthritis who are receiving methotrexate, and who have a previous or
current inadequate response to one prior anti-TNF therapy. All patients will receive MabThera
1000 mg as an intravenous infusion on days 1 and 15. After the initial study phase of 24
weeks, eligible patients may receive one re-treatment with MabThera. The anticipated time on
study treatment is 48 weeks.